Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7713831 | 0.98 | CYP2C19 (0.35) | CYP2C19 | |
| SCHEMBL15571664 | 0.93 | — | — | |
| SCHEMBL30970932 | 0.85 | — | — | |
| SCHEMBL4589011 | 0.73 | CYP2C19 (0.33) | CYP2C19AKR1C1 | |
| SCHEMBL28428585 | 0.70 | CYP2C19 (0.31) | CYP2C19 | |
| SCHEMBL15114541 | 0.70 | FFAR3 (0.39) | CYP2C19 | |
| SCHEMBL27350595 | 0.70 | CYP2C19 (0.31) | CYP2C19 | |
| SCHEMBL949694 | 0.70 | CYP2C19 (0.31) | CYP2C19 | |
| SCHEMBL7385907 | 0.70 | FFAR3 (0.39) | CYP2C19 | |
| SCHEMBL16369946 | 0.68 | FFAR3 (0.37) | CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4649157-A2 | ACYLOIN CONDENSATION REACTIONS, ENZYMES, AND PRODUCTS THEREOF | Mojia Biotech Pte. Ltd. (SG) | 2025-11-19 | — | — | EP | claimed |
| WO-2024150067-A2 | ACYLOIN CONDENSATION REACTIONS, ENZYMES, AND PRODUCTS THEREOF | MOJIA BIOTECH PTE. LTD. (SG) | 2024-07-18 | — | — | WO | claimed |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TUDAG TU DRESDEN AKTIENGESELLSCHAFT (DE) | 2026-03-31 | — | — | US | disclosed |
| EP-4649157-A2 | ACYLOIN CONDENSATION REACTIONS, ENZYMES, AND PRODUCTS THEREOF | Mojia Biotech Pte. Ltd. (SG) | 2025-11-19 | — | — | EP | disclosed |
| WO-2024150067-A2 | ACYLOIN CONDENSATION REACTIONS, ENZYMES, AND PRODUCTS THEREOF | MOJIA BIOTECH PTE. LTD. (SG) | 2024-07-18 | — | — | WO | disclosed |
| CN-116847844-A | Camptothecine antibody-drug conjugates and methods of use thereof | R.P.谢勒技术有限责任公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2023277656-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | (주)스파크바이오파마 | 2023-01-05 | — | — | WO | disclosed |
| EP-3873658-A1 | METHOD FOR PRODUCING MICROPARTICLES WHICH ARE CHARGED WITH AN ACTIVE MATERIAL | BASF SE (DE) | 2021-09-08 | — | — | EP | disclosed |
| US-20210187005-A1 | PHARMACEUTICAL COMPOSITION | KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION (JP) | 2021-06-24 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-10993960-B1 | Pharmaceutical composition | KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION (JP) | 2021-05-04 | — | — | US | disclosed |
| US-6365172-B1 | SELF-REINFORCED BIOABSORBABLE DEVICE COMPRISED OF FUSED OR SINTERED FIBERS MADE FROM BIOABSORBABLE POLYMER COMPRISING SPECIFIED POLYESTERAMIDE | BIOAMIDE, INC. | 2002-04-02 | — | — | US | disclosed |
| US-6120788-A | Bioabsorbable triglycolic acid poly(ester-amide)s | BIOAMIDE, INC. (US) | 2000-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210187005-A1 | PHARMACEUTICAL COMPOSITION | ABCB11, ABCB1, ABCG2 | CYP2C19 614/4885AKR1C1 2479/4885 |
| US-10993960-B1 | Pharmaceutical composition | ABCB11, ABCB1, ABCG2 | CYP2C19 614/4885AKR1C1 2479/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | CYP2C19 4431/4885AKR1C1 2816/4885 |
| US-12590963-B2 | Anti-cancer treatment of preselected subjects and screening methods to identify susceptible subjects | TPM4, TPM3, TAGLN2 | CYP2C19 643/4885AKR1C1 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.